March 20, 2018 / 12:12 PM / a month ago

BRIEF-Kalytera Initiates Program To Develop A Novel Cannabinoid-Based Compound For Treatment Of Acute And Chronic Pain

Reuters Staff

1 Min Read

March 20 (Reuters) - Kalytera Therapeutics Inc:

* KALYTERA INITIATES PROGRAM TO DEVELOP A NOVEL CANNABINOID-BASED COMPOUND FOR TREATMENT OF ACUTE AND CHRONIC PAIN

* KALYTERA THERAPEUTICS INC - ‍KALYTERA OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FOR COMPOUND FROM BEETLEBUNG PHARMA, LTD Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.